Bloomberg Law Analysis

Cannabis Use by Attorneys Follows Generational Trends

An attorney’s experience with cannabis depends in part on their age, according to a recent survey by Bloomberg Law. Generational differences in cannabis use illustrate how its changing legal landscape is creating a more cannabis-friendly generation of lawyers.

Pharma Firms Still Trust Board Oversight as Risks Grow

The pharmaceutical industry is operating within a marketplace of heightened risk, according to a Bloomberg Law analysis of Form 10-K filings. But pharma companies aren’t changing their risk governance approach, clearly favoring board oversight over other recommended means.

Cannabis Rescheduling Unlocks Pharma’s Next Frontier

Cannabis’s move to Schedule III of the federal Controlled Substances Act marks a turning point for pharmaceutical companies’ investment in cannabis drug development by removing barriers that deterred them from cannabis under Schedule I and unlocking a lucrative new federal market for cannabis-based prescription drugs.

Financing Crunch Pushes Biotech to Alternative Funding

Biotechnology start-ups burn through cash quickly as they spend money trying to develop successful drugs. When investors turn more risk averse, as in recent years, biotechs look in alternative places for capital, including from private investment in public equity (PIPEs) and via follow-on offerings.

Pharma M&A Deals Reveal Down Decade, Uncertain Future

Deal volumes for pharmaceutical deals were lower in 2023 than they were 10 years ago and have been lower, on average, than the years prior to 2018 and 2019’s highs. Despite signs that deals may have been on an upswing heading into 2024, this year’s numbers so far aren’t encouraging.

Made with Flourish

Agency Challenges in Federal Circuit

Latest Stories

ANALYSIS: Cannabis Use by Attorneys Follows Generational Trends

An attorney’s experience with cannabis depends in part on their age, according to a recent survey by Bloomberg Law. Generational differences in cannabis use illustrate how its changing legal landscape is creating a more cannabis-friendly generation of lawyers.

ANALYSIS: Pharma M&A Deals Reveal Down Decade, Uncertain Future

Deal volumes for pharmaceutical deals were lower in 2023 than they were 10 years ago and have been lower, on average, than the years prior to 2018 and 2019’s highs. Despite signs that deals may have been on an upswing heading into 2024, this year’s numbers so far aren’t encouraging.

ANALYSIS: Pharma Firms Still Trust Board Oversight as Risks Grow

The pharmaceutical industry is operating within a marketplace of heightened risk, according to a Bloomberg Law analysis of Form 10-K filings. But pharma companies aren’t changing their risk governance approach, clearly favoring board oversight over other recommended means.

ANALYSIS: Cannabis Rescheduling Unlocks Pharma’s Next Frontier

Cannabis’s move to Schedule III of the federal Controlled Substances Act marks a turning point for pharmaceutical companies’ investment in cannabis drug development by removing barriers that deterred them from cannabis under Schedule I and unlocking a lucrative new federal market for cannabis-based prescription drugs.

ANALYSIS: Financing Crunch Pushes Biotech to Alternative Funding

Biotechnology start-ups burn through cash quickly as they spend money trying to develop successful drugs. When investors turn more risk averse, as in recent years, biotechs look in alternative places for capital, including from private investment in public equity (PIPEs) and via follow-on offerings.

ANALYSIS: The Silver Lining to Young Lawyers’ Well-Being Worries

Young lawyers are suffering more well-being problems, such as anxiety and depression, than their older colleagues, according to recent survey results from Bloomberg Law. But they also may be the age group best at getting the help that they need to overcome those issues.

EXPLORE BLOOMBERG LAW

Get the latest legal, regulatory, and enforcement news and analysis, as well as in-depth business and industry covering in the following areas: